Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$33.60
+0.27 (+0.82%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-35.0M · quality 63.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.2B
P/E
N/A
•EV/EBITDA
71.4x
↑ROE
-0.6%
↓Gross Margin
44.2%
↓Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.4%
FCF CAGR
—
FCF margin
-8.6%
FCF / Net income
2.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $406.4M · net income $-11.9M · FCF $-35.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $406.4M | $406.4M | $333.1M | $414.3M | $411.5M |
| Net Income | $-11.9M | $-11.9M | $-28.1M | $91.0M | $106.5M |
| EBITDA | $62.0M | $62.0M | $20.3M | $144.9M | $155.6M |
| EPS | -0.08 | -0.08 | -0.18 | 0.59 | 0.70 |
| Gross Margin | 44.2% | 44.2% | 42.8% | 42.9% | 48.0% |
| Operating Margin | 3.3% | 3.3% | -17.4% | 14.6% | 21.8% |
| Net Margin | -2.9% | -2.9% | -8.4% | 22.0% | 25.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.04 | — | — |
| Current Ratio | 7.57 | 7.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-35.0M | $-35.0M | $-257.7M | $-32.6M | $-158.0M |
| Returns | |||||
| ROE | -0.6% | -0.6% | -1.3% | 4.0% | 4.8% |
| Valuation | |||||
| P/E | — | — | — | 42.20 | 46.84 |
| EV/EBITDA | 71.39 | 71.39 | 137.62 | 17.09 | 28.17 |
| P/B | 2.43 | 2.43 | 1.35 | 1.69 | 2.25 |
| Growth & Yield | |||||
| Revenue Growth | 22.0% | 22.0% | -19.6% | 0.7% | — |
| EPS Growth | 57.4% | 57.4% | -131.4% | -16.3% | — |
| Dividend Yield | 0.6% | 0.6% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+55.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.18 → -0.08
Residual
+54.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.